VJHemOnc is committed to improving our service to you

ASCO 2017 | Understanding the RPL10 R98S mutation in T-ALL

VJHemOnc is committed to improving our service to you

Kim Kampen

Kim Kampen, PhD, University of Leuven, Leuven, Belgium, talks to us about the recent discovery of the ribosomal protein L10 (RPL10) R98S mutation, which occurs in 8% of pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases. Currently, researchers are working to understand the mechanism, drive and cause of the mutation with the aim of using this information to determine potential therapeutic targets for treatment of T-ALL. She mentions that T-ALL patients carrying the mutation have been shown to express higher levels of Bcl2, a pro-survival protein, which raises the possibility of targeting Bcl2 to treat the disease. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter